Company news
Tg Therapeutics, Inc. (NASDAQ:TGTX) news
Tg Therapeutics, Inc. news releases on 6ix. Latest, Sep 23, 2021: TG Therapeutics Announces Publication of Results from an Integrated Safety Analysis…
Press releases — page 4
TG Therapeutics Announces Publication of Results from an Integrated Safety Analysis of UKONIQ® (umbralisib) in Blood Advances
September 22, 2021
TG Therapeutics Announces Combination Data Presentations at the XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL)
September 19, 2021
TG Therapeutics Recaps Schedule of Upcoming Data Presentations at the XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL)
September 12, 2021
TG Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
September 8, 2021
TG Therapeutics Announces Data Presentations at the Upcoming XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL)
August 29, 2021
TG Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results
August 1, 2021
TG Therapeutics to Host Conference Call on Second Quarter 2021 Financial Results and Business Update
July 27, 2021
TG Therapeutics to Participate in the Ladenburg Thalmann 2021 Healthcare Conference
July 8, 2021
TG Therapeutics Mourns the Loss of Board Member, William J. Kennedy, PhD
June 28, 2021
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at 7th Congress of the European Academy of Neurology
June 17, 2021
TG Therapeutics Announces Preclinical and Clinical Data Evaluating TG-1701 at the 16th International Congress on Malignant Lymphoma
June 17, 2021
TG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 European Hematology Association Virtual Congress
June 10, 2021
TG Therapeutics Announces Data Presentations at the Upcoming 16th International Congress on Malignant Lymphoma
June 8, 2021
TG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 American Society of Clinical Oncology Annual Meeting
June 3, 2021
TG Therapeutics to Present at Upcoming Investor Conferences
May 26, 2021
TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab in Combination with UKONIQ® (umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
May 24, 2021
TG Therapeutics Announces Data Presentations at Upcoming Medical Meetings
May 12, 2021
TG Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results
May 9, 2021
TG Therapeutics to Host Conference Call on First Quarter 2021 Financial Results and Business Update
May 5, 2021
TG Therapeutics to Participate in the B. Riley Securities Neuroscience Conference
April 25, 2021
Samsung Biologics and TG Therapeutics Expand Collaboration for the Large Scale Manufacture of Ublituximab
April 25, 2021
TG Therapeutics Announces Launch of the ULTRA-V Phase 3 Trial Evaluating the Triple Combination of UKONIQ™ (umbralisib), Ublituximab, and Venetoclax
April 20, 2021
TG Therapeutics Announces Positive Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at American Academy of Neurology 73rd Annual Meeting
April 15, 2021
TG Therapeutics to Host Investor & Analyst Event to Preview Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis
April 14, 2021
TG Therapeutics Completes Rolling Submission of Biologics License Application to the U.S. Food and Drug Administration for Ublituximab in Combination with UKONIQ™(umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia
March 28, 2021
TG Therapeutics Announces Publication of Results from the UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Relapsed or Refractory Indolent non-Hodgkin Lymphoma in the Journal of Clinical Oncology
March 8, 2021
TG Therapeutics to Present Results from the ULTIMATE I & II Phase 3 Trials Evaluating Ublituximab in Multiple Sclerosis at the Upcoming American Academy of Neurology 73rd Annual Meeting
March 3, 2021
TG Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
March 3, 2021
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2020 Financial Results
March 1, 2021
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2020 Financial Results and Business Update
February 25, 2021
TG Therapeutics Announces Publication of Final Results from the Phase 3 GENUINE Trial Evaluating Ublituximab Plus Ibrutinib in Patients with Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia in The Lancet Haematology
February 22, 2021
TG Therapeutics Announces FDA Accelerated Approval of UKONIQ™ (umbralisib)
February 4, 2021
TG Therapeutics to Participate in the B. Riley Securities Oncology Investor Conference
January 14, 2021
TG Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 7, 2021
TG Therapeutics Announces Proposed Public Offering of Common Stock
December 13, 2020
TG Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
December 13, 2020
TG Therapeutics Announces Positive Topline Results from the ULTIMATE I & II Phase 3 Studies Evaluating Ublituximab Monotherapy for the Treatment of Patients with Multiple Sclerosis
December 9, 2020
TG Therapeutics Announces Triple Combination Data Presentations at the at the 62nd American Society of Hematology Annual Meeting
December 6, 2020
TG Therapeutics Announces Pivotal Data from the UNITY-CLL and UNITY-NHL Clinical Trials Presented at the 62nd American Society of Hematology Annual Meeting
December 6, 2020
TG Therapeutics Recaps Schedule of Data Presentations at the Upcoming 62nd American Society of Hematology Annual Meeting and Exposition
December 2, 2020
TG Therapeutics Announces Publication of Phase 2 Data Evaluating Umbralisib in Patients with Chronic Lymphocytic Leukemia Who Are Intolerant to Prior BTK or PI3K Inhibitor Therapy in Blood
December 1, 2020
TG Therapeutics Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration for Ublituximab in Combination with Umbralisib as a Treatment for Patients with Chronic Lymphocytic Leukemia
November 30, 2020
TG Therapeutics to Participate in the 3rd Annual Evercore ISI HealthCONx Conference
November 29, 2020
TG Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference
November 12, 2020
TG Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results
November 8, 2020
TG Therapeutics Highlights Data Selected for Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting
November 3, 2020
TG Therapeutics Announces Data Presentations at the Upcoming 62nd American Society of Hematology Annual Meeting and Exposition
November 1, 2020
TG Therapeutics Announces Fast Track Designation Granted by the FDA to Ublituximab in Combination with Umbralisib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia
October 20, 2020
TG Therapeutics Announces FDA Acceptance of New Drug Application for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma and Follicular Lymphoma
August 12, 2020
TG Therapeutics Provides Business Update and Reports Second Quarter 2020 Financial Results
August 9, 2020